Rosai-Dorfman-Destombes disease

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Section editor
Gaurav Goyal, MD
Birmingham, AL

Social-twitter-icon.png GauravGoyalMD
1 regimens on this page
1 variants on this page


Consensus guidelines


All lines of therapy

Cobimetinib monotherapy


FDA-recommended dose
Study Dates of enrollment Evidence
Diamond et al. 2019 (MSK 15-216) 2016-NR Phase 2, <20 pts in this arm (RT)

Note: there were N=2 patients with this type of histiocytosis.

Targeted therapy

28-day cycles


  1. MSK 15-216: Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. link to original article contains dosing details in manuscript link to PMC article PubMed